natgillin/translations-raw huggingface dataset:
After the needle is in, remove the hand used to pinch the skin and use it to hold the syringe barrel.
Ko je igla v koži, odmaknite roko, s katero ste stiskali kožo, in z njo primite valj brizge.
Powder and solvent for solution for injection (powder in a vial (1.3 mg), solvent in a vial (1 ml)).
Prašek in vehikel za raztopino za injiciranje (prašek v viali (1,3 mg), vehikel v viali (1 ml)).
Musculoskeletal stiffness*
mišišnoskeletna okorelost*
- Prader-Willi syndrome (PWS), for improvement of growth and body composition.
- Prader-Willijev sindrom (PWS), za izboljšanje rasti in sestave telesa; diagnoza PWS se postavi na podlagi ustreznih genetskih preiskav.
Slipped capital femoral epiphysis and Legg-Calvé-Perthes disease may be considered by your doctor if discomfort or pain in the hip or knee is experienced whilst being treated with Omnitrope.
Zdravnik lahko pomisli na zdrs epifize glavice stegnenice in Legg-Calvé-Perthesovo bolezen, če se med zdravljenjem z zdravilom Omnitrope pojavi nelagodje ali bolečina v kolku ali kolenu.
If you stop using Omnitrope
Če ste prenehali uporabljati zdravilo Omnitrope
In short children/adolescents born SGA, other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment.
Pri otrocih/mladostnikih, ki so se za svojo gestacijsko starost rodili majhni (MGS), je treba pred začetkom zdravljenja izključiti druge zdravstvene težave ali vrste zdravljenja, ki bi lahko pojasnile motnjo pri rasti.
Long-term administration of somatropin to growth hormone deficient patients with osteopenia results in an increase in bone mineral content and density at weight-bearing sites.
Dolgotrajna uporaba somatropina pri bolnikih z osteopenijo in pomanjkanjem rastnega hormona povzroči zvečanje mineralne gostote kosti ter gostote na mestih, ki nosijo telesno maso.
• If you are at risk of developing diabetes, your doctor will need to monitor your blood sugar level during therapy with somatropin.
• Če obstaja tveganje, da se razvije sladkorna bolezen, bo moral zdravnik med zdravljenjem s somatropinom nadzirati vaše vrednosti sladkorja v krvi.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVIN IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
• Reddening, itchiness or pain at the injection site
• pordečitev, srbenje ali bolečina na mestu injiciranja
Based on available literature, hypothalamic-pituitary-adrenal axis can be affected and needs to be re-assessed during growth hormone therapy in growth hormone deficient patients, who were previously not found to be deficient in this axis.
Na podlagi razpoložljivih podatkov iz literature je delovanje osi hipotalamus-hipofiza-nadledvična žleza lahko prizadeto in ga je pri bolnikih s pomanjkanjem rastnega hormona, pri katerih pomanjkljivo delovanje te osi predhodno ni bilo odkrito, med zdravljenjem z rastnim hormonom treba znova ovrednotiti.
- Check for air bubbles in the syringe.
- Preverite, da v brizgi ni zračnih mehurčkov.
The following instructions explain how to inject Omnitrope yourself.
Navodila v nadaljevanju pojasnjujejo, kako si lahko sami injicirate zdravilo Omnitrope.
Reconstituting Omnitrope - Remove the protective cap from the vial.
Priprava zdravila Omnitrope - Odstranite zaščitno zaporko z viale.
Clinical trials in children with Turner syndrome Table 2
Klinična preskušanja pri otrocih s Turnerjevim sindromom Preglednica 2
Remove any air bubbles from the syringe.
Iz brizge odstranite vse zračne mehurčke.
Flip off the plastic protective cap from the vial.
Z viale odtrgajte plastično zaščitno zaporko.
In addition, patients treated with glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses, following initiation of somatropin treatment (see section 4.5).
Pri bolnikih, ki zaradi predhodno ugotovljenega hipoadrenalizma že prejemajo nadomestno zdravljenje z glukokortikoidi, bo po uvedbi zdravljenja s somatropinom morda treba povečati vzdrževalni ali stresni odmerek glukokortikoidov (glejte poglavje 4.5).
Long-term treatment of children with growth disturbance due to born small for gestational age System Organ
Dolgotrajno zdravljenje otrok z motnjami v rasti, ker so se rodili majhni za svojo gestacijsko starost
• If you are receiving treatment with thyroid hormones it may become necessary to adjust your thyroid hormone dose.
• Če se zdravite s ščitničnim hormonom, bo morda treba prilagoditi odmerek ščitničnega hormona.
In patients above 60 years, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements.
Pri bolnikih, starih več kot 60 let, se zdravljenje začne z odmerkom 0,1 - 0,2 mg na dan in se nato postopoma povečuje skladno z bolnikovimi individualnimi potrebami.
Dispose of the syringes safely in a closed container.
Injekcijske brizge varno odložite v zaprto posodo, namenjeno zanje.
Their diagnosis should be considered in a child with a discomfort or pain in the hip or knee.
Pri otrocih z nelagodjem ali bolečino v kolku ali kolenu je treba pomisliti na ti diagnozi.
Turn the vial upside down and using another sterile, disposable syringe of appropriate size (e.g. 1 ml syringe) and injection needle (e.g. 0.25 mm x 8 mm) withdraw a bit more than the dose needed back into the syringe.
Zgornji del viale obrnite navzdol in s pomočjo druge sterilne injekcijske brizge za enkratno uporabo primerne velikosti (npr. 1-mililitrske brizge) ter injekcijske igle (npr. 0,25 mm x 8 mm) prečrpajte nekoliko večjo količino, kot je odmerek, ki ga potrebujete, nazaj v brizgo.
Chronic renal insufficiency Children/adolescents born small for gestational age (SGA)
Motnje rasti pri majhnih otrocih/mladostnikih, ki so se za svojo gestacijsko starost rodili majhni (MGS)
- Hold the syringe with the needle in the vial pointing up and remove the syringe from the vial.
- Brizgo z iglo držite v viali s konico navzgor in jo potegnite iz viale.
Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms.
Najpogostejše sekundarne novotvorbe so bile intrakranialni tumorji, zlasti meningiomi, pri bolnikih, zdravljenih z obsevanjem glave zaradi prve novotvorbe.
Pack sizes of 1, 5 and 10.
Velikosti pakiranja po 1, 5 in 10.
Even higher doses have been used.
Uporabljajo se lahko tudi večji odmerki zdravila.
Intracranial tumours must be inactive and anti-tumour therapy must be completed prior to starting GH therapy.
Intrakranialni tumorji morajo biti nedejavni, zdravljenje tumorja pa se mora končati pred začetkom zdravljenja z rastnim hormonom.
Medical treatment for your kidney should be continued.
Zdravljenje ledvic naj se nadaljuje.
Patients with growth hormone deficiency are characterised by extracellular volume deficit.
Za bolnike s pomanjkanjem rastnega hormona je značilen primanjkljaj zunajcelične prostornine.
If you forget to use Omnitrope
Če ste pozabili vzeti zdravilo Omnitrope
Other adverse drug reactions
Drugi neželeni učinki zdravila
Omnitrope 5 mg/1.5 ml solution for injection: One ml contains 9 mg benzyl alcohol.
Omnitrope 5 mg/1,5 ml raztopina za injiciranje: En ml vsebuje 9 mg benzilalkohola.
Do not share your needles.
Svojih igel ne dajajte drugim.
Use with oral oestrogen therapy
Uporaba skupaj s peroralnim estrogenskim zdravljenjem
Children with Prader-Willi syndrome:
Otroci s Prader-Willijevim sindromom:
In addition, patients already receiving glucocorticoid replacement therapy may need to have the dose of their replacement therapy adjusted, after somatropin treatment is initiated.
Poleg tega pa bo pri bolnikih, ki se že zdravijo z nadomeščanjem glukokortikoidov, po uvedbi zdravljenja s somatropinom morda treba prilagoditi odmerek glukokortikoida pri nadomestnem zdravljenju.
The clinical significance of this is unknown.
Klinični pomen tega dejstva ni znan.
- Gently swirl the reconstituted vial until the content is completely dissolved.
- Pripravljeno vsebino viale narahlo vrtite, dokler se vsebina povsem ne raztopi.
Paraesthesia* Benign intracranial hypertension
Bolezni živčevja parestezija* benigna intrakranialna hipertenzija
Taking into account the PRAC Assessment Report on the PSUR(s) for somatropin, the scientific conclusions of CHMP are as follows:
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za somatropin je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke: Vsa zdravila:
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
Zdravilo se injicira subkutano, mesto injiciranja pa se spreminja in tako prepreči pojav lipoatrofije.
Therefore, in order to achieve an equivalent clinical and biochemical response compared to men dose adjustments may need to be considered by the prescriber in female patients.
Pri bolnicah bo tako za dosego enakovrednega kliničnega in biokemičnega odziva kot pri moških odmerek morda treba prilagoditi.
Somatropin induces the retention of sodium, potassium and phosphorus.
Somatropin povzroči zastajanje natrija, kalija in fosforja v telesu.
The very common and common side effects in adults may start within the first months of treatment and may either stop spontaneously or if your dose is reduced.
Ti zelo pogosti in pogosti neželeni učinki pri odraslih se lahko začnejo prve mesece zdravljenja in izzvenijo spontano ali z zmanjšanjem odmerka.
Powder and solvent for solution for injection (powder in a vial (5 mg), solvent in a cartridge (1 ml)) Pack sizes of 1 and 5.
Prašek in vehikel za raztopino za injiciranje (prašek v viali (5 mg) in vehikel v vložku (1 ml)) Velikosti pakiranja po 1 in 5.
The following is a general description of the administration process.
V nadaljevanju je splošen opis uporabe zdravila.
1 vial of 5 mg powder 1 cartridge of 1 ml solvent 5 vials of 5 mg powder 5 cartridges of 1 ml solvent
1 viala s 5 mg praška 1 vložek z 1 ml vehikla 5 vial s 5 mg praška 5 vložkov z 1 ml vehikla
Use only with Omnitrope Pen L. Read package leaflet before use.
Uporabljajte samo z injekcijskim peresnikom Omnitrope Pen L. Pred uporabo preberite priloženo navodilo!
For guidance on dosing see adult section below.
Glejte spodnje smernice za odmerjanje pri odraslih.
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Solvent for Omnitrope (water for injections with 1.5% benzyl alcohol) Subcutaneous use.
Vehikel za zdravilo Omnitrope (vode za injekcije z 1,5-odstotnim benzilalkoholom)subkutana uporaba
Slipped capital femoral epiphysis and Legg-Calvé-Perthes disease
Zdrs epifize glavice stegnenice in Legg-Calvé-Perthesova bolezen
Based on available literature, higher doses of growth hormone are generally required during the initiation and maintenance phases of treatment in women with an intact hypothalamic-pituitarygonadal axis and on oral oestrogens.
Na podlagi razpoložljivih podatkov iz literature so pri ženskah z intaktno osjo hipotalamus-hipofizaspolne žleze, ki se zdravijo s peroralnimi estrogeni, v začetni in vzdrževalni fazi zdravljenja na splošno potrebni večji odmerki rastnega hormona.
Measuring the dose of Omnitrope to be injected - Take the sterile, disposable syringe of appropriate size (e.g. 1 ml syringe) and injection needle (e.g. 0.25 mm x 8 mm).
Določanje odmerka zdravila Omnitrope, ki ga je treba injicirati - Vzemite sterilno brizgo primerne velikosti za enkratno uporabo (npr. 1-mililitrsko) in injekcijsko iglo (npr. 0,25 mm x 8 mm).
The maintenance dose rarely exceeds 1.0 mg per day.
Dnevni vzdrževalni odmerek redko preseže 1,0 mg na dan.
Use only with Omnitrope Pen 10.
Uporabljajte samo z injekcijskim peresnikom Omnitrope Pen 10.
- The active substance of Omnitrope is somatropin.
- Zdravilna učinkovina v zdravilu Omnitrope je somatropin.
The mean terminal half-life of somatropin after intravenous administration in growth hormone deficient adults is about 0.4 hours.
Pri odraslih s pomanjkanjem rastnega hormona je po intravenski uporabi somatropina srednja končna razpolovna doba okoli 0,4 ure.
Long-term treatment of children with growth disturbance due to chronic renal insufficiency System Organ
Dolgotrajno zdravljenje otrok z motnjami v rasti zaradi kronične ledvične insuficience
Carbohydrate metabolism
Presnavljanje ogljikovih hidratov
The top of the vial and of the cartridge should be wiped with an antiseptic solution in order to prevent contamination of the contents.
Zgornji del viale in vložka obrišite z antiseptično raztopino, da preprečite kontaminacijo vsebine.
Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin.
• levkemija (O njej so poročali pri majhnem številu bolnikov s pomanjkanjem rastnega hormona, pri čemer so bili nekateri zdravljeni s somatropinom.
Push up the plunger slowly back to the correct dose.
Bat počasi potiskajte navzgor, dokler ne odmerite pravega odmerka zdravila.
However, after subcutaneous administration of Omnitrope powder and solvent for solution for injection, a half-life of 3 hours is achieved.
Po subkutani uporabi zdravila Omnitrope prašek in vehikel za raztopino za injiciranje traja razpolovna doba 3 ure.
Higher doses may be necessary if the rate of growth is too low.
Če je stopnja rasti prepočasna, bodo morda potrebni večji odmerki.
Somatropin treatment should be stopped at kidney transplantation.
Ob presaditvi ledvic je treba zdravljenje s somatropinom prekiniti.
Prader-Willi syndrome, for improvement of growth and body composition in paediatric patients Generally a dose of 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day is recommended.
Prader-Willijev sindrom (PWS), za izboljšanje rasti in sestave telesa pri pediatričnih bolnikih Običajen priporočen odmerek je 0,035 mg/kg telesne mase na dan ali 1,0 mg/m telesne površine na dan.
- Turn the vial with the solvent upside down and withdraw all the solvent from the vial.
- Vialo z vehiklom obrnite navzdol in iz nje izčrpajte ves vehikel.
- Take the vial with the powder and push the needle through the rubber membrane of the vial.
- Vzemite vialo s praškom in potisnite iglo skozi gumijasto membrano.
Use only with Omnitrope Pen 5.
Uporabljajte samo z injekcijskim peresnikom Omnitrope Pen 5.
The incidence of these adverse reactions is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency.
Pogostnost pojava teh neželenih reakcij je odvisna od odmerka zdravila, bolnikove starosti in morda v obratnem sorazmerju z njegovo starostjo ob pojavu pomanjkanja rastnega hormona.
Long-term treatment of children with growth disturbance due to insufficient secretion of growth hormone
Dolgotrajno zdravljenje otrok z motnjami v rasti zaradi nezadostnega izločanja rastnega hormona
• Store in the original package in order to protect from light.
• Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Patients and caregivers have to receive appropriate training and instruction on the proper use of the Omnitrope vials, the cartridges with solvent, the transfer set and the pen from the physician or other suitable qualified health professionals.
Zdravniki ali drugo ustrezno usposobljeno osebje morajo bolnike in negovalno osebje ustrezno poučiti o pravilni uporabi vial, vložkov s z vehiklom, seta za prenos in peresnika Omnitrope.
- Adult onset: Patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin.
Odrasli - Nadomestno zdravljenje odraslih z izrazitim pomanjkanjem rastnega hormona - Začetek v odrasli dobi: bolniki, ki imajo hudo pomanjkanje rastnega hormona, povezano s pomanjkanjem številnih hormonov kot posledica znane bolezni hipotalamusa ali hipofize ter ki imajo pomanjkanje najmanj enega hipofiznega hormona, vendar ne prolaktina; diagnozo pomanjkanja rastnega hormona se pri teh bolnikih potrdi ali ovrže z ustreznim dinamičnim testom.
Use only with SurePal 5.
Uporabljajte samo z injekcijskim peresnikom SurePal 5.
In children • Stiffness in the arms and legs
Pri otrocih • togost rok in nog
Your doctor will show you how to inject Omnitrope.
Zdravnik ali sestra vam bo pokazal, kako si injicirati zdravilo Omnitrope.
- Use the transfer set for transferring all the solvent from the cartridge into the vial.
- Vzemite set za prenos, da boste prenesli ves vehikel iz vložka v vialo.
Use the transfer set for transferring the solvent from the cartridge into the vial.
Uporabite set za prenos vehikla iz vložka v vialo.
Do not use Omnitrope
Ne uporabljajte zdravila Omnitrope
- Leave the cartridge in the pen, put the cap on the pen, and store it in the refrigerator.
- Vložek pustite v injekcijskem peresniku, ga zaprite z zaporko in shranite v hladilniku.
Children with Prader-Willi syndrome
Otroci s Prader-Willijevim sindromom
Pack sizes of 1 and 5.
Velikost pakiranja po 1 in 5.
The following instructions explain how to inject Omnitrope 1.3 mg/ml yourself.
Navodila v nadaljevanju pojasnjujejo, kako si lahko sami injicirate zdravilo Omnitrope, 1,3 mg/ml.
1.5 ml of solution in a cartridge (colourless type I glass) with plunger and a blue ring (for Omnitrope 15 mg/1.5 ml solution for injection only) on one side (siliconised bromobutyl), a disc (bromobutyl) and a cap (aluminium) on the other side.
1,5 ml raztopine v vložku (brezbarvno steklo tipa I) z batom in modrim obročkom (samo za zdravilo Omnitrope 15 mg/1,5 ml raztopine za injiciranje) na eni strani (silikonizirani bromobutil), ploščico (bromobutil) ter zaporko (aluminij) na drugi strani.
Use a sterile, disposable syringe (e.g. 2 ml syringe) and needle (e.g. 0.33 mm x 12.7 mm) to withdraw all the solvent from the vial.
Uporabite sterilno injekcijsko brizgo za enkratno uporabo (npr. 2-mililitrsko injekcijsko brizgo) in iglo (npr. 0,33 mm x 12,7 mm), da odstranite ves vehikel iz stekleničke.
Inject the solution by pushing the plunger all the way down gently.
Raztopino injicirajte tako, da počasi potiskate bat navzdol do konca.
Injecting Omnitrope - Put the cartridge with the dissolved Omnitrope into the pen for injection.
Injiciranje zdravila Omnitrope - Vložek z raztopljenim zdravilom Omnitrope vstavite v peresnik za injiciranje.
STATEMENT OF ACTIVE SUBSTANCE Somatropin 6.7 mg (20 IU)/ml.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 6,7 mg somatropina (20 i.e.)/ml.
1.5 ml of solution in a cartridge (colourless type I glass) with plunger on one side (siliconised bromobutyl), a disc (bromobutyl) and a cap (aluminium) on the other side.
1,5 ml raztopine v vložku (brezbarvno steklo tipa I) z batom na eni strani (silikonizirani bromobutil), ploščico (bromobutil) ter zaporko (aluminij) na drugi strani.
Rarely, an inflammation of the pancreas has been reported in patients treated with growth hormone.
Redko so pri bolnikih, zdravljenih z rastnim hormonom, poročali o vnetju trebušne slinavke.
The active substance of Omnitrope is somatropin.
Zdravilna učinkovina v zdravilu Omnitrope je somatropin.
and injection needle (e.g. 0.25 mm x 8 mm) for subcutaneous injection (not supplied in the pack).
(npr. 1-mililitrsko) in injekcijsko iglo (npr. 0,25 mm x 8 mm) za subkutano injiciranje (ki je ni v ovojnini) - 2 blazinici iz vate za čiščenje (ki ju ni v ovojnini).
- Take the vial with solvent and the sterile, disposable syringe (e.g. 2 ml syringe) and needle (e.g. 0.33 mm x 12.7 mm).
- Vzemite vialo z vehiklom in sterilno injekcijsko brizgo za enkratno uporabo (npr. 2-mililitrsko) ter iglo (npr. 0,33 mm x 12,7 mm).
The following instructions explain how to inject Omnitrope 5 mg/ml yourself.
Navodila v nadaljevanju pojasnjujejo, kako si lahko sami injicirate zdravilo Omnitrope, 5 mg/ml.
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Solvent for Omnitrope (water for injections) Subcutaneous use.
Vehikel za zdravilo Omnitrope (voda za injekcije) subkutana uporaba
All patients with PWS should be evaluated for sleep apnoea and monitored if sleep apnoea is suspected.Patients should be monitored for signs of respiratory infections, which should be diagnosed as early as possible and treated aggressively.
Pri vseh bolnikih je treba biti pozoren na morebitne znake okužbe dihal, jih čim prej diagnosticirati in agresivno zdraviti.
The solution is for single use only.
Raztopina je le za enkratno uporabo.
Patients and caregivers have to receive appropriate training and instruction on the proper use of the Omnitrope cartridges and the pen from the physician or other suitable qualified health professionals.
Zdravniki ali drugo ustrezno usposobljeno osebje morajo bolnike in negovalno osebje ustrezno poučiti o pravilni uporabi vložkov in injekcijskega peresnika Omnitrope.
How to use Omnitrope
Kako uporabljati zdravilo Omnitrope
Testing for antibodies to somatropin should be carried out in any patient with otherwise unexplained lack of response.
Sposobnost vezave teh protiteles je majhna in učinka na stopnjo rasti ni. Testiranje za protitelesa za somatropin je treba opraviti pri vseh bolnikih, pri katerih pomanjkanja odziva ni mogoče pojasniti na drugačen način.
The manufacturer's instructions with each pen must be followed for loading the cartridge, attaching the injection needle and for the administration.
Izdelovalčeva navodila, ki so priložena injekcijskemu peresniku, je treba upoštevati pri polnjenju vložka, pritrditvi injekcijske igle in pri uporabi.
Very common side effects (likely to occur in more than 1 in 10 patients) include: In adults
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) vključujejo: Pri odraslih
Omnitrope 5 mg/ml is supplied in a vial containing the active substance as a powder and the solvent filled in a cartridge.
Omnitrope 5 mg/ml je v viali, ki vsebuje zdravilno učinkovino v obliki praška in vehikel v vložku.
- After reconstitution, Omnitrope is given as an injection under the skin.
- Po pripravi se zdravilo Omnitrope injicira pod kožo.
However, after subcutaneous administration of Omnitrope 5 mg/1.5 ml, Omnitrope 10 mg/1.5 ml solution for injection, a half-life of 3 hours is achieved.
Po subkutani uporabi zdravila Omnitrope 5 mg/1,5 ml, Omnitrope 10 mg/1,5 ml raztopina za injiciranje traja razpolovna doba 3 ure.
Although rare, pancreatitis should be considered in somatropin-treated children who develop abdominal pain.
Primeri so sicer redki, vendar pa je pri otroku, ki se zdravi s somatropinom, v primeru pojava bolečine v trebuhu treba pomisliti na pankreatitis.
An increased chromosome fragility has been observed in one in vitro study on lymphocytes taken from patients after long term treatment with somatropin and following the addition of the radiomimetic drug bleomycin.
V preskušanju in vitro na limfocitih, ki so jih odvzeli bolnikom, ki so se dolgo časa zdravili s somatropinom in poleg tega jemali radiomimetično zdravilo bleomicin, se je zvečala krhkost kromosomov.
- Be sure that the tip of the syringe is in the Omnitrope reconstituted solution.
- Prepričajte se, da je konica injekcijske brizge v pripravljeni raztopini zdravila Omnitrope.
This will keep the Omnitrope solution sterile and prevent leaking.
Tako bo raztopina Omnitrope ostala sterilna in ne bo odtekala.
• Numbness/tingling
• otopelost/ščemenje
Assemble the pen following the instructions for use.
Peresnik sestavite tako, kot piše v navodilih za uporabo.
In adults Omnitrope is used to
Zdravilo Omnitrope se uporablja pri odraslih za
However, after subcutaneous administration of Omnitrope 15 mg/1.5 ml solution for injection, a half life of 2.76 hours is achieved.
Po subkutani uporabi zdravila Omnitrope 15 mg/1,5 ml raztopina za injiciranje traja razpolovna doba 2,76 ure.
Other ingredients:
Pomožne snovi:
The glass cartridge is irreversibly integrated in a transparent container and assembled to a plastic mechanism with a threaded rod at one extremity.
Stekleni vložek je neločljivo vgrajen v prozoren vsebnik; na eni strani ima nameščen plastičen mehanizem z nazobčanim potisnikom.